Ocugen, Inc. (OCGN) PT Lowered to $4.50 at Chardan Capital Markets

June 10, 2021 9:48 AM EDT
Get Alerts OCGN Hot Sheet
Price: $2.84 +5.97%

Rating Summary:
    3 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 8 | Down: 40 | New: 22
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Chardan Capital Markets analyst Keay Nakae lowered the price target on Ocugen, Inc. (NASDAQ: OCGN) to $4.50 (from $8.00) while maintaining a Neutral rating after the company announced that it will no longer seek to secure FDA Emergency Use Authorization (EUA) for Bharat Biotech’s Covid-19 vaccine candidate, COVAXIN.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Chardan Capital Markets, FDA